Back to News
Market Impact: 0.38
Novo Signs Delivery Deal With Nanexa Worth Up to $1.3 Billion
Source: Bloomberg
Healthcare & BiotechM&A & RestructuringTechnology & InnovationCompany Fundamentals
Novo Nordisk signed a deal worth up to €1.165 billion ($1.3 billion) with Sweden's Nanexa AB to obtain rights to drug-delivery technology for obesity and diabetes treatments. The agreement strengthens Novo's capabilities in two high-growth therapeutic markets and provides Nanexa with a potentially material commercial validation and revenue opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
NANEXA0.70
NVO0.45
More News
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables
- Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product?
- Stock Movers: UBS, Novo, Hello Fresh (Podcast)
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Research Workflows, Report Format Selection, and Interactive Synthesis
- Can ChatGPT Analyze a 10-K? A Verification Workflow